$SLVM

Sylvamo Corp

No enriched coverage for $SLVM in the last 7 days.

No SEC Form 4 filings for $SLVM in the last 30 days.

Med

Sylvamo (NYSE:SLVM) Earns Buy Rating from Analysts at Truist Financial

Truist Financial initiated coverage on Sylvamo (NYSE:SLVM) with a "Buy" rating and a $54.00 price target, suggesting a potential 34.34% upside. The company recently reported quarterly EPS of $1.08, beating estimates, and revenues of $890 million. While analysts have mixed opinions, the consensus target price for Sylvamo is $55.33.

Sylvamo Corporation $SLVM Shares Sold by Nomura Holdings Inc.

Nomura Holdings Inc. significantly reduced its stake in Sylvamo Corporation (NYSE:SLVM) by 49.1% in the second quarter, selling over 1.5 million shares. This move leaves Nomura Holdings with approximately 3.97% of Sylvamo, valued at $80.3 million. Despite mixed analyst sentiment, with Bank of America upgrading Sylvamo to a Buy, the stock still has a consensus "Hold" rating from analysts.

Sylvamo Delivers Q2 EBITDA Growth

Sylvamo ( NYSE:SLVM ) reported second quarter 2025 results on August 8, delivering adjusted EBITDA of $82 million on a 10% margin and returning nearly $40 million in cash to shareholders despite negative free cash flow and heavy maintenance costs.